{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T06:15:46Z","timestamp":1764828946380,"version":"3.37.3"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T00:00:00Z","timestamp":1643500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T00:00:00Z","timestamp":1643500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s00228-021-03268-w","type":"journal-article","created":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T00:03:06Z","timestamp":1643500986000},"page":"887-889","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Drug-induced hypohidrosis and anhidrosis: analysis of the WHO pharmacovigilance database 2000\u20132020"],"prefix":"10.1007","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6341-6001","authenticated-orcid":false,"given":"Jean-Louis","family":"Montastruc","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genevi\u00e8ve","family":"Durrieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,30]]},"reference":[{"key":"3268_CR1","doi-asserted-by":"crossref","unstructured":"Cheshire Jr WP, Fealey RD (2008) Drug-induced hyperhidrosis and hypohidrosis. incidence, prevention and management. Drug Safety 31:109\u2013126","DOI":"10.2165\/00002018-200831020-00002"},{"key":"3268_CR2","doi-asserted-by":"crossref","unstructured":"Bihan K, Lebrun-Vignes B, Funck-Brentano C, Salem JE (2020) Uses of pharmacovigilance databases: an overview. Therapie 75:591\u20138","DOI":"10.1016\/j.therap.2020.02.022"},{"key":"3268_CR3","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.therap.2019.09.004","volume":"74","author":"N Moore","year":"2019","unstructured":"Moore N, Berda\u00ef D, Blin P, Droz C (2019) Pharmacovigilance - the next chapter. Therapie 74:557\u2013567","journal-title":"Therapie"},{"key":"3268_CR4","doi-asserted-by":"crossref","unstructured":"Mouly S, Roustit M, Bagheri H, Perault-Pochat MC, Molimard M, Bordet R (2019) The French Levothyrox\u00ae\u00a0crisis: We did the best we could but\u2026 Therapie 74:431\u2013435","DOI":"10.1016\/j.therap.2019.01.003"},{"key":"3268_CR5","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","volume":"72","author":"JL Montastruc","year":"2011","unstructured":"Montastruc JL, Sommet A, Bagheri H, Lapeyre-Mestre M (2011) Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol 72:905\u2013908","journal-title":"Br J Clin Pharmacol"},{"key":"3268_CR6","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","volume":"74","author":"JL Faillie","year":"2019","unstructured":"Faillie JL (2019) Case-non-case studies: principle, methods, bias and interpretation. Therapie 74:225\u2013232","journal-title":"Therapie"},{"key":"3268_CR7","unstructured":"Brown JH, Brandi K, Wess J (2018) Muscarinic receptor agonists and antagonists. In: Bruton LL, Hilal-Dandan R, Knollman\u00a0BC (eds) Goodman and Gilman\u2019s The Pharmacological Basis of Therapeutics, 13th edn. Mc Graw Hill Editions, New York,\u00a0pp 149\u2013162"},{"key":"3268_CR8","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1590\/abd1806-4841.201755126","volume":"92","author":"S Delort","year":"2017","unstructured":"Delort S, Marchi E, Corr\u00eaa MA (2017) Oxybutynin as an alternative treatment for hyperhidrosis. An Bras Dermatol 92:217\u2013220","journal-title":"An Bras Dermatol"},{"key":"3268_CR9","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1111\/jdv.14081","volume":"31","author":"L Cruddas","year":"2017","unstructured":"Cruddas L, Baker DM (2017) Treatment of primary hyperhidrosis with oral anticholinergic medications: a systematic review. J Eur Acad Dermatol Venereol 31:952\u2013963","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3268_CR10","first-page":"515","volume":"54","author":"F Incecik","year":"2012","unstructured":"Incecik F, Herg\u00fcner MO, Altunba\u015fak S (2012) Hypohidrosis and hyperthermia during topiramate treatment in children. Turk J Pediatr 54:515\u2013518","journal-title":"Turk J Pediatr"},{"key":"3268_CR11","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1684\/epd.2013.0568","volume":"15","author":"S Karachristianou","year":"2013","unstructured":"Karachristianou S, Papamichalis E, Sarantopoulos A, Boura P, Georgiadis G (2013) Hypohidrosis induced by topiramate in an adult patient. Epileptic Disord 15:203\u2013206","journal-title":"Epileptic Disord"},{"key":"3268_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.107989","volume":"119","author":"V Franco","year":"2021","unstructured":"Franco V, Barbieri MA, Cutroneo PM, Arena I, Cicala G, Marchione P, Spina E, Perucca E (2021) Pediatric adverse reactions to antiseizure medications - an analysis of data from the Italian spontaneous reporting system (2001\u20132019). Epilepsy Behav 119:107989. https:\/\/doi.org\/10.1016\/j.yebeh.2021.107989 (Epub 2021 May 1)","journal-title":"Epilepsy Behav"},{"key":"3268_CR13","unstructured":"Smith MD, MetcalfCS, Wicox KS (2018) Pharmacotherapy of the epilepsies. In:\u00a0LL Brunton, Hilal-Dandan R, Knollmann BC (eds) Goodman and Giman\u2019s The Pharmacological Basis of Therapeutics, 13th edn. Mac Graw Hill. New York, pp\u00a03003\u2013326"},{"key":"3268_CR14","doi-asserted-by":"crossref","unstructured":"Scailteux LM, Lacroix C, Bergeron S, Despas F, Sassier M, Triquet L, Picard S, Oger E, Polard E and the French Network of Pharmacovigilance Centres (2021) Adverse drug reactions profiles for abiraterone and enzalutamide: a pharmacovigilance descriptive analysis. Therapie 76:455\u2013465","DOI":"10.1016\/j.therap.2020.12.012"},{"key":"3268_CR15","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1345\/aph.1C017","volume":"36","author":"C Villier","year":"2002","unstructured":"Villier C, Mallaret MP (2002) Nefopam abuse. Ann Pharmacother 36:1564\u20131566","journal-title":"Ann Pharmacother"},{"key":"3268_CR16","doi-asserted-by":"crossref","unstructured":"Revol B, Delorme J, Jouanjus \u00c9, Spadari M, Djezzar S, Lepelley M, Khouri C, Fouilh\u00e9 Sam-La\u00ef N, Mallaret M (2021) le r\u00e9seau fran\u00e7ais des Centres d\u2019addictovigilance. Thirty years of nefopam abuse in France. Therapie 76:527\u2013537","DOI":"10.1016\/j.therap.2021.01.058"},{"key":"3268_CR17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jclinepi.2021.01.015","volume":"134","author":"C Khouri","year":"2021","unstructured":"Khouri C, Petit C, Tod M, Lepelley M, Revol B, Roustit M, Cracowski JL (2021) Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases. J Clin Epidemiol 134:14\u201321","journal-title":"J Clin Epidemiol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-021-03268-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-021-03268-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-021-03268-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T08:06:45Z","timestamp":1649750805000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-021-03268-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,30]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["3268"],"URL":"https:\/\/doi.org\/10.1007\/s00228-021-03268-w","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2022,1,30]]},"assertion":[{"value":"16 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"According to the clinical research French law, review from an ethics committee is not required for such observational studies. As all data from VigiBase were deidentified, patient informed consent was not necessary. The authors are willing to share source data as requested.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}